Reversal effect of Tween-20 on multidrug resistance in tumor cells in vitro

Shouhui Yang1, Jinjuan Liu, Yongqiang Chen

  • 1Key Laboratory of Biotechnology for Medicinal Plants of Jiangsu Province, Xuzhou Normal University, 101 Shanghai Road, Xuzhou, China.

Insights

Tween-20 effectively reverses multidrug resistance (MDR) in cancer cells by increasing drug accumulation and downregulating MDR gene expression. This non-ionic surfactant enhances chemotherapy sensitivity without significant cytotoxicity.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Cancer Research

Background:

  • Multidrug resistance (MDR) significantly limits chemotherapy efficacy in cancer treatment.
  • Non-ionic surfactants show promise in overcoming MDR.
  • The specific role of Tween-20 in MDR reversal was previously unknown.

Purpose of the Study:

  • To investigate the MDR reversal effects of Tween-20 on cancer cells in vitro.
  • To elucidate the underlying mechanisms of Tween-20's action against MDR.

Main Methods:

  • Alamar Blue assay to determine reversal index with vincristine, doxorubicin, and 5-fluorouracil.
  • Cell morphology assessment using Gimsa and Hoechst 33258 staining.
  • Doxorubicin accumulation measured by spectrofluorimetry.
  • Cell cycle analysis via flow cytometry.
  • MDR gene and protein expression evaluated by RT-PCR and dot blot.

Main Results:

  • Tween-20 exhibited minimal cytotoxicity at tested concentrations (0.0025%-0.01%).
  • It significantly enhanced the sensitivity of MDR cancer cells to chemotherapy drugs.
  • Tween-20 increased doxorubicin accumulation and potentiated vincristine-induced G2/M cell cycle arrest.
  • Downregulation of MDR and P-glycoprotein expression was observed.

Conclusions:

  • Tween-20 effectively reverses the multidrug resistance phenotype in cancer cells.
  • This reversal is achieved by enhancing intracellular drug accumulation.
  • Potential mechanisms involve the inhibition of multidrug-resistant gene expression.

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...